Clinical Breast Cancer

Papers
(The H4-Index of Clinical Breast Cancer is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Letter to the Editor regarding the article “Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World85
Table of Contents54
Letter to the Editor of Clinical Breast Cancer, on “Time to Update Evidence-Based Guideline Recommendations About Concurrent Tamoxifen and Antidepressant Use? A Systematic Review,” Conducted by Michel51
Tumor ki67 Impact on Survival in Male Breast Cancer Patients: A Systematic Review and Meta-Analysis38
Intraoperative Touch Imprint Cytology in Breast Cancer Patients After Neoadjuvant Chemotherapy37
Is Immediate Breast Reconstruction With a Latissimus Dorsi Myocutaneous Flap Safe for Starting Adjuvant Chemotherapy in Patients With Breast Cancer?33
Table of Contents32
Corrigendum to “Prognostic and predictive impact of beta-2 adrenergic receptor expression in HER2-positive breast cancer” [Clin Breast Cancer 2020; 20:262–73.e7]32
Diagnosis, Management, and Surveillance for Patients With PALB2, CHEK2, and ATM Gene Mutations31
Surgical-Site Infection is Associated With Increased Risk of Breast Cancer-Related Lymphedema: A Nationwide Cohort Study31
The Ultrasonographic Characteristics of Focal Fibrocystic Change of the Breast and Analysis of Misdiagnosis29
Editorial Board29
Survivorship Navigation for Young Women With Early-Stage Breast Cancer28
Genetic Ancestry of 1127 Brazilian Breast Cancer Patients and Its Correlation With Molecular Subtype and Geographic Region27
Editorial Board26
A Review of AI-Based Radiomics and Computational Pathology Approaches in Triple-Negative Breast Cancer: Current Applications and Perspectives24
Circ_0108942 Regulates the Progression of Breast Cancer by Regulating the MiR-1178-3p/TMED3 Axis24
A Dedicated Menopausal After Cancer Clinic May Improve Adherence to Endocrine Therapy For Breast Cancer: A Population Based Study24
SPON2 acts as a tumor promoter in HR-positive/HER2-negative breast cancer by regulating β-catenin signaling23
Comprehensive analysis of HER2 Low Breast Cancer Response to Neoadjuvant Chemotherapy, a Retrospective Cohort Study23
Adjuvant Chemotherapy in Early Triple-Negative Breast Cancer (T1a-c N0M0): A Systematic Review and Meta-Analysis23
High Ki-67 expression is associated with increased risk of distant recurrence in Oncotype Dx low risk breast cancer22
The Impact of miRNAs on the Efficacy of Tamoxifen in Breast Cancer Treatment: A Systematic Review22
Development and Validation of Preoperative Ultrasound-Based Risk Scoring Systems for Predicting Axillary Lymph Node Metastasis in Breast Cancer: A Multicenter, Retrospective Study22
Comment on: Prognostic Ability of the Indication for Adjuvant Systemic Therapy Based on Preoperative Biopsy and the Surgical Excision Specimen in Cases of Small Breast Tumors (CONSCIENCE): A Retrospec22
0.08463191986084